XINT — Xintela AB Share Price
Last trade - 00:00- SEK269.59m
- SEK269.15m
- SEK0.08m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 707.59 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -11988.45% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 0.04 | n/a | n/a | n/a | 0.08 | n/a | n/a | -45.54% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Xintela AB (Xintela) is a Sweden-based biomedical company engaged in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumors. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The Company has developed therapeutic antibodies, which bind to cancer cells. It has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.
Directors
- Gregory Batcheller CHM (64)
- Evy Lundgren-Akerlund CEO (59)
- Gunnar Telhammar CFO (58)
- Sven Kili COO (52)
- Rickard Mosell VBD
- Thomas Areschoug OTH
- Caroline Ehrencrona OTH
- Carl-Magnus Hogerkorp OTH (47)
- Liselotte Theorell OTH
- Peter Edman DRC (65)
- Karin Wingstrand DRC (62)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- April 2nd, 2009
- Public Since
- March 22nd, 2016
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 568,760,509
- Address
- Scheeletorget 1, LUND, 223 81
- Web
- https://www.xintela.se/
- Phone
- +46 462756500
- Contact
- Adam Lindblom
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Upcoming Events for XINT
Similar to XINT
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 24:11 UTC, shares in Xintela AB are trading at SEK0.47. This share price information is delayed by 15 minutes.
Shares in Xintela AB last closed at SEK0.47 and the price had moved by +82.31% over the past 365 days. In terms of relative price strength the Xintela AB share price has outperformed the FTSE Global All Cap Index by +57.37% over the past year.
There is no consensus recommendation for this security.
Find out moreXintela AB does not currently pay a dividend.
Xintela AB does not currently pay a dividend.
Xintela AB does not currently pay a dividend.
To buy shares in Xintela AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK0.47, shares in Xintela AB had a market capitalisation of SEK269.59m.
Here are the trading details for Xintela AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: XINT
Based on an overall assessment of its quality, value and momentum Xintela AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Xintela AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +63.51%.
As of the last closing price of SEK0.47, shares in Xintela AB were trading +49.91% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Xintela AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Xintela AB's management team is headed by:
- Gregory Batcheller - CHM
- Evy Lundgren-Akerlund - CEO
- Gunnar Telhammar - CFO
- Sven Kili - COO
- Rickard Mosell - VBD
- Thomas Areschoug - OTH
- Caroline Ehrencrona - OTH
- Carl-Magnus Hogerkorp - OTH
- Liselotte Theorell - OTH
- Peter Edman - DRC
- Karin Wingstrand - DRC